Bone Marrow & Stem Cell Transplant

Longer follow-up from the NMDP's ACCESS trial emphasizes the opportunity to use mismatched stem cell donors in more diverse patient populations.

A retrospective analysis showed 2-year survival outcomes of over 13,000 patients receiving allogeneic hematopoietic cell transplants by donor source.

Phase 2 interim safety data presented at the EBMT 2026 Annual Meeting suggest no additive toxicity with the novel combination chronic GVHD regimen.

Adding itacitinib to posttransplant cyclophosphamide and tacrolimus proved safe and well tolerated, with low GVHD rates and no nonrelapse mortality.

ABC trial interim results demonstrate effective, short-duration prophylaxis without conventional immunosuppressants and with dose-reduced cyclophosphamide.

Most patients with heavily pretreated chronic GVHD experienced clinical benefit with axatilimab, with the majority continuing treatment after approval.

Post-transplant gilteritinib maintenance may boost survival and reduce relapse in relapsed FLT3-mutated AML, though larger trials are still needed.

Phase 3 results show that fecal microbiotherapy achieved a 62% GI response rate and a 54% 1-year survival in patients who had failed both corticosteroids and ruxolitinib.

Fifty patients are enrolled to receive EBX-102-02 or placebo to address gut microbiome disruption associated with allogeneic hematopoietic cell transplant.

A validated analysis of nearly 22,000 patients receiving allogeneic hematopoietic cell transplant led to development of a risk calculator for acute graft-vs-host disease.

A trial found that off-the-shelf TRX103 Tr1 cells were safe to use after a mismatched donor stem cell transplant, showing engraftment, dose-dependent expansion, and persistence.

A phase 2 trial of acalabrutinib led to favorable response rates and tolerability in steroid-refractory chronic GVHD.

A trial of ustekinumab as graft-vs-host disease (GVHD) prophylaxis after hematopoietic cell transplant did not meet its primary end point but showed more favorable outcomes in patients who had myeloablative conditioning.

Higher doses of anti–T-lymphocyte globulin significantly reduce chronic graft-vs-host disease in matched sibling stem cell transplants, enhancing patient outcomes.

Leyla O. Shune, MD, discusses results from an interim safety analysis of a randomized phase 2 study exploring axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease.

Leyla O. Shune, MD, discusses an expanded access program in the United States that administered axatilimab to patients with chronic graft-versus-host disease. Specifically, she highlights the tolerability of axatilimab in the real-world setting.

Leyla O. Shune, MD, describes the available treatment options for patients with chronic graft-versus-host disease who are steroid refractory/dependent. She also discusses treatment approaches and results with these agents in clinical trials and in real-world settings.

During a live event, Hannah Choe, MD, analyzed key findings from the AGAVE-201 trial of axatilimab in chronic graft-vs-host disease.

Addressing Treatment Challenges in Chronic Graft-Versus-Host Disease

Orca-T immunotherapy shows promising results in improving survival and reducing complications in patients with hematologic malignancies compared to traditional treatments.

New research reveals mismatched unrelated donors significantly improve transplant outcomes, expanding options for diverse patients in need of life-saving procedures.

MaaT013 shows promising efficacy and safety in treating refractory GI-aGVHD, offering hope for improved survival in patients.

New findings reveal the feasibility and safety of transitioning axatilimab dosing for chronic graft-vs-host disease, showing promising response rates.

The ACCESS study reveals that posttransplant cyclophosphamide improves survival rates for patients with mismatched unrelated donor transplants, expanding donor options.